MW 314.36 Da, Purity >98%. Selective cyclooxygenase-2 inhibitor (IC50 values are 3.8 and >100 μM for COX-2 and COX-1, respectively). Orally active. Anti-inflammatory, antipyretic, analgesic and non-ulcerogenic in vivo. Induces apoptosis and cell cycle arrest.
Select an associated product type
Cyclooxygenase, Cyclooxygenase 2b, Cyclooxygenase 3, included, Cyclooxygenase-1, Cyclooxygenase-2, EC 1.14.99.1, GRIPGHS, Glucocorticoid-regulated inflammatory Prostaglandin G/H synthase, Glucocorticoid-regulated inflammatory cyclooxygenase, Macrophage activation-associated marker protein P71/73, OTTHUMP00000033524, PCOX1, PES-2, PGG/HS, PGH synthase 1, PGH synthase 2, PGH1_HUMAN, PGH2_HUMAN, PGHS-1, PGHS-2, PHS 1, PHS 2, PHS II, PTGHS, PTGS1, PTGS2, Partial COX1 proteins, included, Prostaglandin G/H synthase, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Prostaglandin G/H synthase 2 precursor, Prostaglandin G/H synthase and cyclooxygenase, Prostaglandin H2 synthase 1, Prostaglandin H2 synthase 2, Prostaglandin-endoperoxide synthase 1, Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase), Prostaglandin-endoperoxide synthase 2, TIS10, TIS10 protein, fj02a10, hCox 2, prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase), ptgs2a, unp1239, wu:fj02a10
MW 314.36 Da, Purity >98%. Selective cyclooxygenase-2 inhibitor (IC50 values are 3.8 and >100 μM for COX-2 and COX-1, respectively). Orally active. Anti-inflammatory, antipyretic, analgesic and non-ulcerogenic in vivo. Induces apoptosis and cell cycle arrest.
Soluble in DMSO to 100 mM.
Selective cyclooxygenase-2 inhibitor (IC50 values are 3.8 and >100 μM for COX-2 and COX-1, respectively). Orally active. Anti-inflammatory, antipyretic, analgesic and non-ulcerogenic in vivo. Induces apoptosis and cell cycle arrest.
Cyclooxygenase 2 (COX2) and Cyclooxygenase 1 (COX1) are enzymes that convert arachidonic acid into prostaglandins which are involved in inflammation and other physiological functions. COX2 also known as prostaglandin-endoperoxide synthase 2 has a molecular mass of approximately 72 kDa. COX1 sometimes called prostaglandin-endoperoxide synthase 1 has similar molecular weight. These enzymes are expressed in various tissues with COX1 found ubiquitously and COX2 expressed more selectively often induced by inflammatory stimuli.
COX2 and COX1 help regulate processes like inflammation pain and fever through their role in prostaglandin synthesis. COX1 primarily maintains normal cellular processes while COX2 is highly inducible and becomes active during inflammatory responses. COX2 does not typically form complexes operating independently in the cellular environment to mediate inflammatory signals.
COX2 and COX1 are key components in the prostaglandin biosynthetic pathway influencing pain and inflammatory pathways. Their activity affects the cyclooxygenase pathway important for converting arachidonic acid into prostaglandins and thromboxanes. COX enzymes interact closely with other proteins like prostaglandin synthases and thromboxane synthase which further modify their products into different prostaglandins and thromboxanes.
COX2 links to conditions such as rheumatoid arthritis and colorectal cancer. Its increased expression often correlates with the inflammatory response seen in these illnesses. Inhibiting COX2 with drugs like lumiracoxib alleviates symptoms in inflammatory diseases. COX1 while less implicated in disease connects to interactions with other proteins indicating changes during digestive issues due to its role in gastric mucosa maintenance.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2D chemical structure image of ab120295, NS 398, COX-2 inhibitor
Anti-p27 KIP 1 antibody [Y236] ab32034 staining p27 KIP1 in MCF7 cells treated with NS 398 (ab120295), by ICC/IF. Increase in p27 KIP1 expression correlates with increased concentration of NS 398, as described in literature.
The cells were incubated at 37°C for 6h in media containing different concentrations of ab120295 (NS 398) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with Anti-p27 KIP 1 antibody [Y236] ab32034 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (Goat Anti-Rabbit IgG H&L (DyLight® 488) preadsorbed ab96899) at 1/250 dilution was used as the secondary antibody.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com